NCT07271186

Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of ANGPTL3 Inhibition With Either Small-Interfering RNA Alone or in Combination With an ANGPTL3 Antibody in Participants With Diabetic Kidney Disease

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 270 (estimated)
• Sponsor: Regeneron Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is researching experimental drugs called ALN-ANG3 and evinacumab (called "study drugs"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times

Conditions

• Diabetic Kidney Disease (DKD)

Interventions

Type	Name	Description
DRUG	ALN-ANG3	Administered per the protocol
DRUG	Evinacumab	Administered per the protocol
DRUG	ALN-ANG3 placebo	Administered per the protocol
DRUG	Evinacumab placebo	Administered per the protocol

Timeline

• Start date: 2026-01-09
• Primary completion: 2027-09-24
• Completion: 2028-04-07
• First posted: 2025-12-09
• Last updated: 2026-04-16

Locations

39 sites across 1 country: United States

Regulatory

• FDA-regulated drug study